Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-05-06
- Target Recruit Count
- 1506
- Registration Number
- NCT02866175
- Locations
- 🇺🇦
Kharkiv City Clinical Hospital #8, Kharkiv, Ukraine
🇬🇧Altnagelvin Area Hospital, Londonderry, United Kingdom
🇬🇧Golden Jubilee Hospital, Clydebank, United Kingdom
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Faculty Hospital Kralovske Vinohrady
- Target Recruit Count
- 1226
- Registration Number
- NCT02808767
- Locations
- 🇨🇿
Faculty Hospital Kralovske Vinohrady, Prague, Czechia
Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT02798874
- Locations
- 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China
Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 200
- Registration Number
- NCT02792712
- Locations
- 🇨🇳
Teipei Veterans General Hospital, Taipei, Taiwan
Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02762864
Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02748330
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Campus Bio-Medico University
- Target Recruit Count
- 42
- Registration Number
- NCT02742987
The Effect of IV Cangrelor and Oral Ticagrelor Study
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
- Target Recruit Count
- 100
- Registration Number
- NCT02733341
- Locations
- 🇬🇧
The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Wuhan Asia Heart Hospital
- Target Recruit Count
- 477
- Registration Number
- NCT02699008
- Locations
- 🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China
Ticagrelor Versus Clopidogrel in Carotid Artery Stenting
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 210
- Registration Number
- NCT02677545
- Locations
- 🇨🇭
Kantonsspital Aarau Klinik für Neurologie, Aarau, Switzerland
🇮🇹Ospedale Civile di Mirano, Department of Cardiology, Mirano, Italy
🇧🇪Ghent University Hospital - Dept thoracic and vascular surgery, Ghent, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.